In conclusion, NF-κB inhibitors remain a potential therapeutic treatment for RV-induced asthma exacerbation; however, future research into drug combinations such as corticosteroids and NF-κB inhibitors, multiple NF-κB inhibitors or inhibitors of other transcription factors such as AP-1 and C/EBP may pave the way for more therapeutic options. Here, CEBPA is linked to asthma.